Septerna Inc SEPN

$41.53 -1.07 (-2.51%)

Valuation

Market cap
2,025,587,000
Revenue TTM
$45,950,000
Net income TTM
$-48,880,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-106.38%
Debt to equity
0.00

Trading

Volume
183,922
Avg volume
403,514
Day's range
$40.99 – $43.00
Shares out
47,549,000
Stochastic %K
16%
Beta
2.20
Analysts
Strong Buy
Price target
$59.22

Price

Company profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric m...

Show more

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 338 3533
Website
https://www.septerna.com
Address
250 East Grand Avenue, South San Francisco, United States

Latest news

Stocktwits

shoc24 Nov 10, 6:17 AM
$SEPN reported earnings after the close today. GAAP EPS missed estimates: -$0.57 vs. -$0.41 expected, according to Stock Meadow.
0 replies
MisterRagnirLothbrok Nov 5, 12:37 AM
Ticker SCAG had huge news today: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $AICU $SEPN $SKE $SKK Xi0
0 replies
27R Aug 17, 3:38 PM
$SEPN Buckle up — earnings after the close today.
0 replies
EMPIR3_37 Aug 7, 1:55 PM
$SEPN This thing has been an absolute money printer for over a year now.
1 replies
ItsTheEagle Jul 16, 7:34 PM
$SEPN high risk, high potential reward. Took a small position here
0 replies
MadStockAlerts1 Jul 8, 1:16 PM
$SEPN watch it 🔥
0 replies
MadStockAlerts1 Jul 8, 5:26 AM
$SEPN 🔥 isn't making noise, it's making progress. Moving averages are stacked in the right order and the uptrend hasn't broken stride once. That's the kind of quiet, deliberate action that we love to see 🦾
0 replies
topstockalerts Jul 8, 1:32 AM
$SEPN the action here feels increasingly deliberate.
0 replies